Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

This page features the latest news about the Upstream Bio stock. OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares OrbiMed Advisors LLC, a prominent shareholder in Upstream Bio ...

Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, visits the Nasdaq ...

The global upstream bioprocessing equipment market was valued at approximately US$ 7.75 billion in 2022 and is expected to ...

Upstream Bio valued at $1.1 bln in stellar debut as healthcare IPOs heat up October 11, 2024 Upstream Bio, two other U.S. biotech startups price IPOs as healthcare listings rise October 11 ...

Upstream Bio (UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public offering. Read more here.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Upstream Bio (NASDAQ:UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public offering. Shares of Upstream (UPB) opened at $21.50, later reaching a high ...